STMN.SW Straumann Holding AG (SIX) pre-market CHF97.14 19 Feb 2026: heavy volume

Pre-market action shows STMN.SW stock trading at CHF 97.14 on 19 Feb 2026 with volume 917,712, making it one of Switzerland’s most active names in early trading. The move follows mixed longer-term returns — year-to-date up 3.01% but one-year down 24.43% — while liquidity spikes push relative volume to 2.30. Traders should note the immediate price context, the healthcare sector backdrop, and the coming earnings calendar for Straumann Holding AG on the SIX exchange.

STMN.SW stock snapshot and pre-market flow

STMN.SW stock is quoted at CHF 97.14 with a one-day change of +0.82 (0.85%). Pre-market volume is 917,712 versus average volume 399,153, a relative volume of 2.30, signalling above-normal trading interest. Day range shows CHF 92.60 to CHF 104.50 while the 12-month range is CHF 83.10 to CHF 134.45. Market capitalisation stands near CHF 15,489,055,278.00.

STMN.SW stock fundamentals and valuation

Straumann reports EPS of 2.69 and a trailing PE of 36.11, above the healthcare sector average PE of 34.32. Price-to-sales is about 6.12 and price-to-book near 7.65, indicating a premium valuation. The company pays CHF 0.95 per share in dividends, a yield around 0.96%. Key balance metrics: debt-to-equity is 0.20, current ratio 1.64, and ROE roughly 19.17%.

STMN.SW stock performance drivers and sector context

Straumann’s revenue growth for FY 2024 was 3.82%, while net income grew 57.81% year-over-year, driven by margin improvements. The company operates in Medical – Instruments & Supplies and competes inside Healthcare, where average PE is 34.32. Major sales drivers: dental implants, ClearCorrect aligners and CAD/CAM prosthetics. Watch the next scheduled earnings announcement on 2026-08-18, which is a potential catalyst for directional moves.

STMN.SW stock technicals and trading signals

Short-term technicals are neutral to constructive: RSI 51.21, MACD 0.31 with signal 0.29, and Bollinger Bands at Upper 101.37 and Lower 91.23. The 50-day average is 95.996 and the 200-day average is 97.96, placing price slightly above the 50-day and near the 200-day. High pre-market volume and an On-Balance Volume trend suggest active accumulation in the session.

Meyka AI grade and STMN.SW stock forecast

Meyka AI rates STMN.SW with a score out of 100: the model gives a 75.89 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month price of CHF 97.66, compared with the current price of CHF 97.14, implying a modest upside of 0.54%. Forecasts are model-based projections and not guarantees.

STMN.SW stock risks, price targets and trading plan

Key risks include a stretched valuation, extended inventory days (222.82), and modest interest coverage (2.75). Short-term support aligns with the Bollinger lower band near CHF 91.23; immediate resistance sits near CHF 101.37. Realistic price targets: conservative CHF 85.00, base case CHF 97.00, and bullish CHF 115.00. For most-active traders, watch volume confirmation and intraday breaks of CHF 101.37 or CHF 91.23 before committing.

Final Thoughts

STMN.SW stock is an active pre-market trade on 19 Feb 2026 after volume spiked to 917,712, more than double its average. Straumann’s fundamentals show profitable margins, EPS 2.69, and ROE near 19.17%, but valuation multiples (PE 36.11, PB 7.65) leave limited margin for error. The healthcare sector backdrop is supportive but competitive. Meyka AI’s short-term projection of CHF 97.66 implies only +0.54% upside from CHF 97.14, suggesting the market currently prices in the company’s growth and premium positioning. Active traders should prioritise volume-confirmed breakouts and monitor the 50/200-day moving average interplay. Long-term investors should weigh Straumann’s durable brand and product pipeline against valuation and working-capital dynamics. This analysis is data-driven and produced by Meyka AI, an AI-powered market analysis platform — forecasts are projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.